Adipokines in health and disease

Trends in Pharmacological Sciences

Volumn 36, Issue 7, 2015, Pages 461-470

  Fasshauer, Mathias ^a   Blüher, Matthias ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

adipokines; adipose tissue; obesity; type 2 diabetes mellitus

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; APELIN; BONE MORPHOGENETIC PROTEIN 4; CATHEPSIN K; CATHEPSIN L; CATHEPSIN S; CHEMERIN; CLUSTERIN; COMPLEMENT FACTOR D; DIPEPTIDYL PEPTIDASE IV; FATTY ACID BINDING PROTEIN 4; FETUIN A; FIBROBLAST GROWTH FACTOR 21; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OSTEOGENIC PROTEIN 1; PROGRANULIN; RESISTIN; RETINOL BINDING PROTEIN 4; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN; VASPIN; WNT1 PROTEIN; BIOLOGICAL MARKER;

ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; ENERGY EXPENDITURE; FOOD INTAKE; GENE EXPRESSION PROFILING; HEMOSTASIS; HUMAN; INSULIN RELEASE; METABOLIC DISORDER; MOLECULAR DYNAMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; REVIEW; ANIMAL; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; SECRETION (PROCESS);

ADIPOKINES; ADIPOSE TISSUE; ANIMALS; BIOMARKERS; DIABETES MELLITUS, TYPE 2; HUMANS; OBESITY;

EID: 84932199132     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2015.04.014     Document Type: Review

References (103)

1. L.F. Van Gaal Mechanisms linking obesity with cardiovascular disease Nature 444 2006 875 880
2. D. LeRoith Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence Exp. Clin. Endocrinol. Diabetes 116 2008 S4 S6
3. M. Blüher Importance of adipokines in glucose homeostasis Diabetes Manage. 3 2013 389 400
4. N. Klöting, and M. Blüher Adipocyte dysfunction, inflammation and metabolic syndrome Rev. Endocr. Metab. Disord. 15 2014 277 287
5. M. Blüher Adipose tissue dysfunction contributes to obesity related metabolic diseases Best Pract. Res. Clin. Endocrinol. Metab. 27 2013 163 177
6. E.E. Kershaw, and J.S. Flier Adipose tissue as an endocrine organ J. Clin. Endocrinol. Metab. 89 2004 2548 2556
7. S. Lehr Adipokines: a treasure trove for the discovery of biomarkers for metabolic disorders Proteomics Clin. Appl. 1-2 2012 91 101
8. S. Lehr Identification and validation of novel adipokines released from primary human adipocytes Mol. Cell. Proteomics 11 2012 10.1074/mcp.M111.010504 M111.010504
9. I. Dahlman Functional annotation of the human fat cell secretome Arch. Physiol. Biochem. 118 2012 84 91
10. M. Blüher, and C.S. Mantzoros From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century Metabolism 64 2015 131 145
11. M. Blüher Adipokines: removing road blocks to obesity and diabetes therapy Mol. Metab. 3 2014 230 240
12. M. Blüher Clinical relevance of adipokines Diabetes Metab. J. 36 2012 317 327
13. P. Björntorp, and L. Sjöström Number and size of adipose tissue fat cells in relation to metabolism in human obesity Metab. Clin. Exp. 20 1971 703 713
14. A. Cotillard Adipocyte size threshold matters: link with risk of type 2 diabetes and improved insulin resistance after gastric bypass J. Clin. Endocrinol. Metab. 99 2014 E1466 E1470
15. T. Skurk Relationship between adipocyte size and adipokine expression and secretion J. Clin. Endocrinol. Metab. 92 2007 1023 1033
16. N. Klöting Insulin-sensitive obesity Am. J. Physiol. Endocrinol. Metab. 299 2010 E506 E515
17. J. Laurencikiene Regulation of lipolysis in small and large fat cells of the same subject J. Clin. Endocrinol. Metab. 96 2011 E2045 E2049
18. D. Schleinitz The genetics of fat distribution Diabetologia 57 2014 1276 1286
19. Y. Zhang Fat cell size and adipokine expression in relation to gender, depot, and metabolic risk factors in morbidly obese adolescents Obesity 22 2014 691 697
20. N. Klöting Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass Cell Metab. 6 2007 79 87
21. R. Chakaroun Effects of weight loss and exercise on chemerin serum concentrations and adipose tissue expression in human obesity Metabolism 61 2012 706 714
22. B.S. Youn Serum progranulin concentrations may be associated with macrophage infiltration into omental adipose tissue Diabetes 58 2009 627 636
23. G. Flehmig Identification of adipokine clusters related to parameters of fat mass, insulin sensitivity and inflammation PLoS ONE 9 2014 e99785
24. K.S. Cook Adipsin: a circulating serine protease homolog secreted by adipose tissue and sciatic nerve Science 237 1987 402 405
25. J.S. Flier Severely impaired adipsin expression in genetic and acquired obesity Science 237 1987 405 408
26. J.C. Lo Adipsin is an adipokine that improves β cell function in diabetes Cell 158 2014 41 53
27. P.K. Siiteri Adipose tissue as a source of hormones Am. J. Clin. Nutr. 45 1987 277 282
28. Y. Zhang Positional cloning of the mouse obese gene and its human homologue Nature 372 1994 425 432
29. I.S. Farooqi Effects of recombinant leptin therapy in a child with congenital leptin deficiency N. Engl. J. Med. 341 1999 879 884
30. J.P. Foo, and C.S. Mantzoros Leptin in congenital or HIV-associated lipodystrophy and metabolic syndrome: a need for more mechanistic studies and large, randomized, placebo-controlled trials Metabolism 61 2012 1331 1336
31. C.S. Mantzoros Leptin in human physiology and pathophysiology Am. J. Physiol. Endocrinol. Metab. 301 2011 E567 E584
32. M. Fasshauer Adipokines in gestational diabetes Lancet Diabetes Endocrinol. 2 2014 488 499
33. Heymsfield Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial JAMA 282 1999 1568 1575
34. C.J. Hukshorn Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men J. Clin. Endocrinol. Metab. 85 2000 4003 4009
35. J.D. Roth Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies Proc. Natl. Acad. Sci. U.S.A. 105 2008 7257 7262
36. E. Ravussin Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy Obesity 17 2009 1736 1743
37. H.S. Moon Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals Endocr. Rev. 34 2013 377 412
38. M. Dalamaga Leptin at the intersection of neuroendocrinology and metabolism: current evidence and therapeutic perspectives Cell Metab. 18 2013 29 42
39. R. Ye, and P.E. Scherer Adiponectin, driver or passenger on the road to insulin sensitivity? Mol. Metab. 2 2013 133 141
40. P.E. Scherer A novel serum protein similar to C1q, produced exclusively in adipocytes J. Biol. Chem. 270 1995 26746 26749
41. E. Hu AdipoQ is a novel adipose-specific gene dysregulated in obesity J. Biol. Chem. 271 1996 10697 10703
42. K. Maeda cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1) Biochem. Biophys. Res. Commun. 221 1996 286 289
43. A.T. Turer, and P.E. Scherer Adiponectin: mechanistic insights and clinical implications Diabetologia 55 2012 2319 2326
44. M. Okamoto Adiponectin induces insulin secretion in vitro and in vivo at a low glucose concentration Diabetologia 51 2008 827 835
45. M. Okada-Iwabu A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity Nature 503 2013 493 499
46. T. Kadowaki Adiponectin and its receptors: implications for obesity-associated diseases and longevity Lancet Diabetes Endocrinol. 2 2014 8 9
47. Z.J. Wu Adiponectin is associated with increased mortality in patients with already established cardiovascular disease: a systematic review and meta-analysis Metabolism 63 2014 1157 1166
48. M.G. Karas Relations of plasma total and high-molecular-weight adiponectin to new-onset heart failure in adults >/=65 years of age (from the Cardiovascular Health study) Am. J. Cardiol. 113 2014 328 334
49. M. Cote Adiponectin and risk of coronary heart disease in apparently healthy men and women (from the EPIC-Norfolk Prospective Population Study) Am. J. Cardiol. 108 2011 367 373
50. E. Sook Lee Association between adiponectin levels and coronary heart disease and mortality: a systematic review and meta-analysis Int. J. Epidemiol. 42 2013 1029 1039
51. J. Spranger Adiponectin and protection against type 2 diabetes mellitus Lancet 361 2003 226 228
52. N. Itoh FGF21 as a hepatokine, adipokine, and myokine in metabolism and diseases Front. Endocrinol. 5 2014 107
53. G. Gaich The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes Cell Metab. 18 2013 333 340
54. A. Kharitonenkov FGF-21 as a novel metabolic regulator J. Clin. Invest. 115 2005 1627 1635
55. F.M. Fisher FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis Genes Dev. 26 2012 271 281
56. X. Cheng Serum FGF-21 levels in type 2 diabetic patients Endocr. Res. 36 2011 142 148
57. A. Kharitonenkov, and A.C. Adams Inventing new medicines: the FGF21 story Mol. Metab. 3 2014 221 229
58. W. Wei Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma Proc. Nat. Acad. Sci. U.S.A. 109 2012 3143 3148
59. Y. Zhang The starvation hormone, fibroblast growth factor-21, extends lifespan in mice Elife 1 2012 e00065
60. T.J. Schulz Brown-fat paucity due to impaired BMP signalling induces compensatory browning of white fat Nature 495 2013 379 383
61. T.J. Schulz, and Y.H. Tseng Emerging role of bone morphogenetic proteins in adipogenesis and energy metabolism Cytokine Growth Factor Rev. 20 2009 523 531
62. Y.H. Tseng New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure Nature 454 2008 1000 1004
63. K.L. Townsend Bone morphogenetic protein 7 (BMP7) reverses obesity and regulates appetite through a central mTOR pathway FASEB J. 26 2012 2187 2196
64. A.R. Vaccaro The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft for posterolateral lumbar arthrodesis: minimum 4-year follow-up of a pilot study Spine J. 8 2008 457 465
65. B. Gustafson, and U. Smith The WNT inhibitor Dickkopf 1 and bone morphogenetic protein 4 rescue adipogenesis in hypertrophic obesity in humans Diabetes 61 2012 1217 1224
66. B. Gustafson BMP4 and BMP antagonists regulate human white and beige adipogenesis Diabetes 64 2015 1670 1681
67. A.M. Cypess Identification and importance of brown adipose tissue in adult humans N. Engl. J. Med. 360 2009 1509 1517
68. W.D. van Marken Lichtenbelt Cold-activated brown adipose tissue in healthy men N. Engl. J. Med. 360 2009 1500 1508
69. K.A. Virtanen Functional brown adipose tissue in healthy adults N. Engl. J. Med. 360 2009 1518 1525
70. K. Hida Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity Proc. Natl. Acad. Sci. U.S.A. 102 2005 10610 10615
71. B.S. Youn Serum vaspin concentrations in human obesity and type 2 diabetes Diabetes 57 2008 372 377
72. M. Blüher Vaspin in obesity and diabetes: pathophysiological and clinical significance Endocrine 41 2012 176 182
73. N. Klöting Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effects Diabetologia 54 2011 1819 1823
74. J.T. Heiker Vaspin inhibits kallikrein 7 by serpin mechanism Cell. Mol. Life Sci. 70 2013 2569 2583
75. J. Boucher Apelin, a newly identified adipokine up-regulated by insulin and obesity Endocrinology 146 2005 1764 1771
76. I. Castan-Laurell Apelin, diabetes, and obesity Endocrine 40 2011 1 9
77. K. Kuba Impaired heart contractility in Apelin gene-deficient mice associated with aging and pressure overload Circ. Res. 101 2007 e32 e42
78. P. Yue Apelin decreases lipolysis via G(q), G(i), and AMPK-dependent mechanisms Endocrinology 152 2011 59 68
79. J. Cao Targeting drugs to APJ receptor: the prospect of treatment of hypertension and other cardiovascular diseases Curr. Drug Targets 16 2015 148 155
80. G. Frühbeck Regulation of adipocyte lipolysis Nutr. Res. Rev. 27 2014 63 93
81. J. Krist Effects of weight loss and exercise on apelin serum concentrations and adipose tissue expression in human obesity Obes. Facts 6 2013 57 69
82. M. Sorhede Winzell The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice Regul. Pept. 131 2005 12 17
83. C. Dray Apelin stimulates glucose utilization in normal and obese insulin-resistant mice Cell Metab. 8 2008 437 445
84. J.E. Campbell, and D.J. Drucker Pharmacology, physiology, and mechanisms of incretin hormone action Cell Metab. 17 2013 819 837
85. M.A. Nauck Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications Am. J. Med. 124 2011 S3 S18
86. D.J. Drucker Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls Diabetes 62 2013 3316 3323
87. E.E. Mulvihill, and D.J. Drucker Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors Endocr. Rev. 35 2014 992 1019
88. D. Lamers Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome Diabetes 60 2011 1917 1925
89. H. Sell Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro Diabetes Care 36 2013 4083 4090
90. S.S. Das Regulation of dipeptidyl peptidase 4 production in adipocytes by glucose Diabetes Metab. Syndr. Obes. 7 2014 185 194
91. D. Röhrborn Shedding of dipeptidyl peptidase 4 is mediated by metalloproteases and up-regulated by hypoxia in human adipocytes and smooth muscle cells FEBS Lett. 588 2014 3870 3877
92. S.J. Dunmore, and J.E.P. Brown The role of adipokines in β-cell failure of type 2 diabetes J. Endocrinol. 216 2013 T37 T45
93. W.P. Cawthorn, and J.K. Sethi TNF-alpha and adipocyte biology FEBS Lett. 582 2008 117 131
94. G.S. Hotamisligil Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance Science 259 1993 87 91
95. K.T. Uysal Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function Nature 389 1997 610 614
96. Z. Li Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease Hepatology 37 2003 343 350
97. H. Liang Blockade of tumor necrosis factor (TNF) receptor type 1-mediated TNF-alpha signaling protected Wistar rats from diet-induced obesity and insulin resistance Endocrinology 149 2008 2943 2951
98. I. Hmamouchi Early increase of abdominal adiposity in patients with spondyloarthritis receiving anti-tumor necrosis factor-α treatment J. Rheumatol. 41 2014 1112 1117
99. T.C. Wascher Chronic TNF-alpha neutralization does not improve insulin resistance or endothelial function in 'healthy' men with metabolic syndrome Mol. Med. 17 2011 189 193
100. C.M. Larsen Interleukin-1-receptor antagonist in type 2 diabetes mellitus N. Engl. J. Med. 356 2007 1517 1526
101. C.J. Tack Inflammation links excess fat to insulin resistance: the role of the interleukin-1 family Immunol. Rev. 249 2012 239 252
102. D. Gao Interleukin-1β mediates macrophage-induced impairment of insulin signaling in human primary adipocytes Am. J. Physiol. Endocrinol. Metab. 307 2014 E289 E304
103. E. Dalmas T cell-derived IL-22 amplifies IL-1β-driven inflammation in human adipose tissue: relevance to obesity and type 2 diabetes Diabetes 63 2014 1966 1977